Concepedia

The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system

Zheng Yang, Yu Meng, Mei Mei, Chongxin Chen, Yuhuan Lv, Linyu Xiang, Rong Li

Nutrition Metabolism and Cardiovascular Diseases · 2021 · 34 citations · 14 references

DOI

Concepts

References

14

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text

, , +13

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

, , +14

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

, , +17

Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports

Stephen Evans, Patrick Waller, Sarah Davis · Pharmacoepidemiology and Drug Safety · 2001 · 1.7K citations

, , +16

9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Medical Care in Diabetes—2022</i>

Diabetes Care · 2021 · 1.5K citations

, , +13